CorMedix (CRMD)

Executive Summary

CorMedix Inc. (NASDAQ: CRMD) is a biopharmaceutical company focused on developing and commercializing therapies for infectious and inflammatory diseases in hospital and acute care settings. Its lead product candidate, DefenCath (taurolidine/heparin lock solution), is a non-antibiotic catheter lock solution designed to reduce catheter-related bloodstream infections in hemodialysis patients with central venous catheters. DefenCath has received Fast Track and Qualified Infectious Disease Product (QIDP) designations from the FDA, underscoring its potential to address a significant unmet medical need. The company is preparing for a potential commercial launch, having built out a sales force and distribution infrastructure. With a strong safety and efficacy profile from clinical trials, DefenCath could become a standard-of-care in preventing life-threatening infections in a vulnerable patient population, representing a substantial market opportunity.

Upcoming Catalysts (preview)

• Q1 2026FDA Approval Decision for DefenCath80% success
• Q1 2026Commercial Launch of DefenCath in the U.S.70% success
• Q2 2026Reimbursement and Payer Coverage Decisions60% success